GSK Sp ADR (GSK)
$36.75
0.22 (0.60%)
GSK Stock Quote Delayed 30 Minutes
3 Big Stock Charts for Tuesday: Morgan Stanley, Ross Stores and Dominion Energy
The stock charts of ROST, D and MS are shaping up as the top trading prospects as December's action gets going.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$39.01
Market Cap
157.60B
PE Ratio
59.08
EPS
0.622
Volume (Avg. Vol.)
10.60M
Day's Range
$36.27 - $37.98
52-Week Range
$31.37 - $44.37
Dividend & Yield
$1.55 (4.23%)
GSK Stock Predictions, Articles, and GSK Sp ADR News
3 Ways to Unpack Some Hidden Treasure in Tesaro Stock
TSRO stock has had a difficult 2018, but it could offer some sizable gains later down the road. Here are three ways to play Tesaro.
GlaxoSmithKline Is More Than Just a 5% Dividend Income Play
GlaxoSmithKline pays shareholders a solid dividend yet the company is not just for income investors. In the next few years, growth in the consumer unit will lead to strong cash flow, raising the chances of dividend hikes for GSK stock.
5 Top Stock Trades for Thursday Morning
Stocks were able to bounce back on Wednesday, leading many investors to brush off Tuesday's decline. Here are our top stock trades for Thursday.
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
GlaxoSmithKline plc Shares Sink on Q1 Earnings Miss
GlaxoSmithKline (GSK) stock was down on Wednesday following the release of an earnings report that misses estimates for the first quarter of 2018.
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018.
Pfizer Inc. Stock Owners Should Brace for This Possibility
Reports show that not many companies are interested in Pfizer's (PFE) consumer health arm. Here's what they're balking at and what it means for PFE stock owners.
GlaxoSmithKline’s (GSK) Upgraded to Hold
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Hold. The methodology for fundamental and quantitative metrics used in this analytical tool, developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week. The shares have been upgraded from a Sell to a Hold in the last week.
Metrics for Quant Score Make GlaxoSmithKline (GSK) a Sell
GlaxoSmithKline Plc (NYSE:GSK) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 781 company GICS Health Care sector. GSK has a market value of $85.7 billion which is in the top 10% of its industry group. The ranking for GSK by Portfolio Grader places it 87 among the 133 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 503 among the 781 companies in the sector, and number 3,192 in the nearly 5,000 company Portfolio Grader universe.
Slumping Earnings Visibility Make GlaxoSmithKline (GSK) a Sell
GlaxoSmithKline Plc (NYSE:GSK) is one of 132 companies within the Pharmaceuticals GICS industry group, which is in turn part of the 782 company GICS Health Care sector. GSK's market value is $86.3 billion which places it in the top decile in its industry group. The ranking for GSK by Portfolio Grader places it 88 among the 132 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 511 among the 782 companies in the sector, and number 3,219 in the nearly 5,000 company Portfolio Grader universe.
Deleterious Earnings Momentum Drop GlaxoSmithKline (GSK) to Sell
GlaxoSmithKline Plc (NYSE:GSK) is a $88.4 billion in market value constituent of the Pharmaceuticals GICS industry group where The current Portfolio Grader ranking for GSK puts it 77 among the 133 companies in this industry group, giving it a below-average spot. GSK is ranked in the third quartile of the sector with a ranking of 499 among the 785 companies in the sector and number 3,205 in the 5000 company Portfolio Grader company universe.
Stock of GlaxoSmithKline (GSK) Lowered to Sell
Portfolio Grader currently ranks GlaxoSmithKline Plc (NYSE:GSK) a Sell. The methodology for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. The current overall Portfolio Grader recommendation on the shares has changed twice in the past month, which represents a greater level of change than is typical.
